trial · primary record
Duvelisib
Recurrent Chronic Lymphocytic Leukemia
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 15 |
| Primary completion | 2027-10-25 |
| Primary endpoint | Progression Free Survival (PFS) at 12 Months |
| Registry ID | NCT03961672 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:44:38.271Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03961672
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.